The COVID-19 vaccine from Noubar Afeyan's Modern Inc may me ready by the end of this year, Reuters reported referring to US officials.

The company has earlier announced a late phase trial of the vaccine in 30,000 volunteers to demonstrate that it is safe and effective.

These are the first tests being carried out as part of the government's program, which aims to accelerate the development, production and distribution of drugs and vaccines for COVID-19.

The US government has allocated about a billion dollars to the Moderna project and has selected a vaccine developed by the company for large-scale human trials.

According to the company, the main goal of the study is to prevent symptomatic manifestations of the disease.